Aethlon Medical Sets August 13 Date for First Quarter Earnings Call

Management will initiate the session shortly after the market closes at 4:15 p.m. ET. Following a presentation of the quarterly performance, the company will open the floor for a question-and-answer period. Interested investors are encouraged to register online to receive specific dial-in instructions, though toll-free and international phone lines remain available for those without internet access.

Aethlon Medical continues to focus on its proprietary lectin-based technology, specifically the Hemopurifier, which holds FDA Breakthrough Device designation for treating advanced metastatic cancer and certain life-threatening viral infections. A replay of the conference call will be accessible on the company website and via designated phone lines starting one hour after the event concludes, remaining available through September 13, 2026.